Abbott integrates precision oncology tests with Flatiron's OncoEMR platform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform
March 30, 2026 9:00 AM EDTBroadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment decisionsAllows oncologists to order tests and view results directly in the clinical workflow
ABBOTT PARK, Ill. and NEW YORK, March 30, 2026 /PRNewswire/ -- Abbott (NYSE:... More
